Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "inflammatory"

198 News Found

Biocon partner Equillium initiates clinical study for Itolizumab in Lupus Nephritis
Biotech | December 24, 2021

Biocon partner Equillium initiates clinical study for Itolizumab in Lupus Nephritis

Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000


Pfizer to acquire Arena Pharmaceuticals for US $ 6.7 bn
News | December 14, 2021

Pfizer to acquire Arena Pharmaceuticals for US $ 6.7 bn

The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases


Glenmark subsidiary, Ichnos Sciences and Almirall enter exclusive licencing agreement
Biotech | December 14, 2021

Glenmark subsidiary, Ichnos Sciences and Almirall enter exclusive licencing agreement

Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales


Zydus to begin Phase II (a) clinical trial of ZYIL1 in Australia
Biotech | December 13, 2021

Zydus to begin Phase II (a) clinical trial of ZYIL1 in Australia

It is a novel oral NLRP3 inflammasome inhibitor


Daiichi Sankyo initiates Phase 3 trial for Destiny-Breast11 neoadjuvant therapy
Biotech | November 30, 2021

Daiichi Sankyo initiates Phase 3 trial for Destiny-Breast11 neoadjuvant therapy

Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab


Arrowhead Pharmaceuticals enters agreement with GSK to develop NASH drug candidate
Biotech | November 24, 2021

Arrowhead Pharmaceuticals enters agreement with GSK to develop NASH drug candidate

Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales


Fortis Escorts Faridabad introduces Cryo technique to treat lung cancer
Hospitals | November 24, 2021

Fortis Escorts Faridabad introduces Cryo technique to treat lung cancer

Cryo-technology helps in early diagnosis and palliative care in later stages of cancer


Mandaviya launches the sixth edition of National Formulary of India (NFI)
Public Health | October 29, 2021

Mandaviya launches the sixth edition of National Formulary of India (NFI)

The NFI is published to promote the rational use of medicines in the country.


Rainbow hospital gives new lease of life to infant on ECMO support
Healthcare | October 28, 2021

Rainbow hospital gives new lease of life to infant on ECMO support

The youngest child in India to survive ECMO after undergoing bone marrow transplant for a rare disease


Novartis cancer drug trial does not meet primary end points
Biotech | October 25, 2021

Novartis cancer drug trial does not meet primary end points

The company is continuing with the evaluation of canakinumab in lung cancer, and is applying findings to the overall lung cancer development plan